Helus Pharma Inc.
HELP
Get informed when a big investor buys or sells
+ FollowMarket Cap$413.02M
Close$
Share Statistics
| Market cap | $413.02 Million |
|---|---|
| Enterprise Value | $358.16 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -71.55% |
|---|---|
| Return on Assets | -54.87% |
| Return on Invested Capital | -70.34% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.03 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cybin Inc
100 employees
CEO: Michael I. Halstead Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer fr...